Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Expanded antigen-specific donor regulatory T cells for GVHD prevention.

Blood·2026

Same author

Publisher Correction: Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma.

Nature cancer·2026

Same author

Publisher Correction: Single-cell epigenetic and transcriptomic states across the continuum of monoclonal B cell lymphocytosis to chronic lymphocytic leukemia.

Genome biology·2026

Same author

Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma.

Nature cancer·2026

Same author

Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Unfinished business in chronic lymphocytic leukemia: translational and clinical priorities for a cure.

Blood·2026

Search research articles

Related Experiment Video

Updated: Nov 9, 2025

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Published on: May 10, 2017

Splice it up: Atypical transcripts to boost leukemia immunotherapy.

Nicoletta Cieri¹, Catherine J Wu²

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.

|April 14, 2021

Summary

This summary is machine-generated.

Identifying cancer neoantigens for immunotherapy is difficult in low mutational burden cancers. This study reveals that atypical transcripts, including retained introns, offer new leukemia immunotherapy targets.

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

Related Experiment Videos

Last Updated: Nov 9, 2025

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Published on: May 10, 2017

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

Area of Science:

Oncology
Immunology
Genomics

Background:

Neoantigens are crucial targets for effective cancer immunotherapy.
Identifying neoantigens is particularly challenging in low mutational burden cancers, such as certain leukemias.
Current methods often miss potential targets in these malignancies.

Purpose of the Study:

To investigate novel sources of neoantigens beyond traditional mutations.
To explore the potential of atypical transcripts as immunotherapy targets in leukemia.
To overcome the limitations of neoantigen discovery in low mutational burden cancers.

Main Methods:

Analysis of atypical RNA transcripts in leukemia samples.
Focus on identifying non-coding and aberrant RNA species.
Validation of identified targets for potential immunotherapeutic applications.

Main Results:

Atypical transcripts, especially retained introns, were identified as a significant source of neoantigens.
These atypical transcripts expand the repertoire of potential targets for leukemia immunotherapy.
The findings demonstrate a novel strategy for neoantigen discovery.

Conclusions:

Retained introns and other atypical transcripts represent a promising avenue for expanding cancer immunotherapy targets.
This approach can enhance the efficacy of immunotherapies, particularly in challenging low mutational burden cancers.
The study provides a new framework for neoantigen identification in leukemia.